Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission

Nicholas J Short; Walid Macaron; Tapan Kadia; Courtney Dinardo; Ghayas C Issa; Naval Daver; Sa Wang; Jeff Jorgensen; Daniel Nguyen; Aram Bidikian; Keyur P Patel; Sanam Loghavi; Marina Konopleva; Musa Yilmaz; Elias Jabbour; Abhishek Maiti; Hussein A Abbas; Elizabeth Shpall; Uday Popat; Gheath Al-Atrash; Sherry Pierce; Hagop M Kantarjian; Farhad Ravandi

doi:10.1002/ajh.26698

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission

Am J Hematol. 2022 Nov;97(11):E408-E411. doi: 10.1002/ajh.26698. Epub 2022 Sep 8.

Authors

Nicholas J Short¹, Walid Macaron¹, Tapan Kadia¹, Courtney Dinardo¹, Ghayas C Issa¹, Naval Daver¹, Sa Wang², Jeff Jorgensen², Daniel Nguyen³, Aram Bidikian¹, Keyur P Patel², Sanam Loghavi², Marina Konopleva¹, Musa Yilmaz¹, Elias Jabbour¹, Abhishek Maiti¹, Hussein A Abbas¹, Elizabeth Shpall⁴, Uday Popat⁴, Gheath Al-Atrash⁴, Sherry Pierce¹, Hagop M Kantarjian¹, Farhad Ravandi¹

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
⁴ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 36054774
DOI: 10.1002/ajh.26698

Abstract

Recurrence of MRD in AML is associated with imminent relapse unless intervened upon. Change in chemotherapy regimen and/or immediate transplant improve outcomes.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Neoplasm, Residual
Prognosis
Recurrence

Grants and funding

CA016672/University of Texas MD Anderson Cancer Center